The rational use of animal models in the evaluation of novel bone regenerative therapies

Bone

Volumn 70, Issue , 2015, Pages 73-86

  Peric, Mihaela ^a   Dumic Cule, Ivo ^a   Grcevic, Danka ^a   Matijasic, Mario ^a   Verbanac, Donatella ^a   Paul, Ruth ^b   Grgurevic, Lovorka ^a   Trkulja, Vladimir ^a   Bagi, Cedo M ^c   Vukicevic, Slobodan ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b Paul Regulatory Services Ltd   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

Animal model; Bone fracture; Bone healing; Healing parameters; Regenerative therapy; Tools for scoring

Indexed keywords

BIOMATERIAL;

ANIMAL MODEL; ANIMAL WELLBEING; BIOTECHNOLOGY; BONE DEFECT; BONE REGENERATION; BONE REMODELING; CELL THERAPY; DISEASE SEVERITY; DOG; EXPERIMENTAL STUDY; METHODOLOGY; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OUTCOME ASSESSMENT; PRIMATE; RABBIT; REVIEW; RODENT; SAMPLE SIZE; SCORING SYSTEM; SHEEP; STANDARDIZATION; SWINE; THERAPY EFFECT; TREATMENT INDICATION; VALIDITY; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HUMAN; PROCEDURES; REGENERATIVE MEDICINE; STATISTICS; WOUND HEALING;

ANIMALS; BIOCOMPATIBLE MATERIALS; BONE REGENERATION; DISEASE MODELS, ANIMAL; HUMANS; REGENERATIVE MEDICINE; STATISTICS AS TOPIC; WOUND HEALING;

EID: 84918568550     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.07.010     Document Type: Review

References (241)

1. Hernlund E., Svedbom A., Ivergard M., Compston J., Cooper C., Stenmark J., et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013, 8:136.
2. Svedbom A., Hernlund E., Ivergard M., Compston J., Cooper C., Stenmark J., et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013, 8:137.
3. Kalfas I.H. Principles of bone healing. Neurosurg Focus 2001, 10:E1.
4. Keating A. Mesenchymal stromal cells. Curr Opin Hematol 2006, 13:419-425.
5. Homma Y., Zimmermann G., Hernigou P. Cellular therapies for the treatment of non-union: the past, present and future. Injury 2013, 44(Suppl. 1):S46-S49.
6. Rozen N., Bick T., Bajayo A., Shamian B., Schrift-Tzadok M., Gabet Y., et al. Transplanted blood-derived endothelial progenitor cells (EPC) enhance bridging of sheep tibia critical size defects. Bone 2009, 45:918-924.
7. Khosla S., Westendorf J.J., Modder U.I. Concise review: Insights from normal bone remodeling and stem cell-based therapies for bone repair. Stem Cells 2010, 28:2124-2128.
8. Schmidt-Bleek K., Schell H., Schulz N., Hoff P., Perka C., Buttgereit F., et al. Inflammatory phase of bone healing initiates the regenerative healing cascade. Cell Tissue Res 2012, 347:567-573.
9. Fayaz H.C., Giannoudis P.V., Vrahas M.S., Smith R.M., Moran C., Pape H.C., et al. The role of stem cells in fracture healing and nonunion. Int Orthop 2011, 35:1587-1597.
10. Schroeder J.E., Mosheiff R. Tissue engineering approaches for bone repair: concepts and evidence. Injury 2011, 42:609-613.
11. Shekkeris A.S., Jaiswal P.K., Khan W.S. Clinical applications of mesenchymal stem cells in the treatment of fracture non-union and bone defects. Curr Stem Cell Res Ther 2012, 7:127-133.
12. Cook S.D., Baffes G.C., Wolfe M.W., Sampath T.K., Rueger D.C. Recombinant human bone morphogenetic protein-7 induces healing in a canine long-bone segmental defect model. Clin Orthop Relat Res 1994, 302-312.
13. Paralkar V.M., Borovecki F., Ke H.Z., Cameron K.O., Lefker B., Grasser W.A., et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci U S A 2003, 100:6736-6740.
14. Dimitriou R., Tsiridis E., Giannoudis P.V. Current concepts of molecular aspects of bone healing. Injury 2005, 36:1392-1404.
15. Vo T.N., Kasper F.K., Mikos A.G. Strategies for controlled delivery of growth factors and cells for bone regeneration. Adv Drug Deliv Rev 2012, 64:1292-1309.
16. Vukicevic S., Sampath T.K. Bone Morphogenetic Proteins: From Laboratory to Clinical Practice 2002, Birkhauser Verlag, Basel-Boston-Berlin.
17. Vukicevic S., Oppermann H., Verbanac D., Jankolija M., Popek I., Curak J., et al. The clinical use of bone morphogenetic proteins revisited: a novel biocompatible carrier device OSTEOGROW for bone healing. Int Orthop 2014, 38:635-647.
18. Kanczler J.M., Oreffo R.O. Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cell Mater 2008, 15:100-114.
19. Gerber H.P., Vu T.H., Ryan A.M., Kowalski J., Werb Z., Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999, 5:623-628.
20. Eckardt H., Ding M., Lind M., Hansen E.S., Christensen K.S., Hvid I. Recombinant human vascular endothelial growth factor enhances bone healing in an experimental nonunion model. J Bone Joint Surg Br 2005, 87:1434-1438.
21. Leach J.K., Kaigler D., Wang Z., Krebsbach P.H., Mooney D.J. Coating of VEGF-releasing scaffolds with bioactive glass for angiogenesis and bone regeneration. Biomaterials 2006, 27:3249-3255.
22. Ozturk B.Y., Inci I., Egri S., Ozturk A.M., Yetkin H., Goktas G., et al. The treatment of segmental bone defects in rabbit tibiae with vascular endothelial growth factor (VEGF)-loaded gelatin/hydroxyapatite "cryogel" scaffold. Eur J Orthop Surg Traumatol 2013, 23:767-774.
23. Friedlaender G.E., Lin S., Solchaga L.A., Snel L.B., Lynch S.E. The role of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) in orthopaedic bone repair and regeneration. Curr Pharm Des 2013, 19:3384-3390.
24. Fei Y., Gronowicz G., Hurley M.M. Fibroblast growth factor-2, bone homeostasis and fracture repair. Curr Pharm Des 2013, 19:3354-3363.
25. Mountziaris P.M., Spicer P.P., Kasper F.K., Mikos A.G. Harnessing and modulating inflammation in strategies for bone regeneration. Tissue Eng Part B Rev 2011, 17:393-402.
26. Mountziaris P.M., Mikos A.G. Modulation of the inflammatory response for enhanced bone tissue regeneration. Tissue Eng Part B Rev 2008, 14:179-186.
27. Kempen D.H., Lu L., Hefferan T.E., Creemers L.B., Heijink A., Maran A., et al. Enhanced bone morphogenetic protein-2-induced ectopic and orthotopic bone formation by intermittent parathyroid hormone (1-34) administration. Tissue Eng Part A 2010, 16:3769-3777.
28. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
29. Almeida J.D., Arisawa E.A., da Rocha R.F., Carvalho Y.R. Effect of calcitonin on bone regeneration in male rats: a histomorphometric analysis. Int J Oral Maxillofac Surg 2007, 36:435-440.
30. Bosetti M., Boccafoschi F., Leigheb M., Cannas M.F. Effect of different growth factors on human osteoblasts activities: a possible application in bone regeneration for tissue engineering. Biomol Eng 2007, 24:613-618.
31. Zhang W., Zhu C., Wu Y., Ye D., Wang S., Zou D., et al. VEGF and BMP-2 promote bone regeneration by facilitating bone marrow stem cell homing and differentiation. Eur Cell Mater 2014, 27:1-12.
32. Ramazanoglu M., Lutz R., Rusche P., Trabzon L., Kose G.T., Prechtl C., et al. Bone response to biomimetic implants delivering BMP-2 and VEGF: an immunohistochemical study. J Craniomaxillofac Surg 2013, 41:826-835.
33. Hernandez A., Reyes R., Sanchez E., Rodriguez-Evora M., Delgado A., Evora C. In vivo osteogenic response to different ratios of BMP-2 and VEGF released from a biodegradable porous system. J Biomed Mater Res A 2012, 100:2382-2391.
34. Reyes R., De la Riva B., Delgado A., Hernandez A., Sanchez E., Evora C. Effect of triple growth factor controlled delivery by a brushite-PLGA system on a bone defect. Injury 2012, 43:334-342.
35. Cui Q., Dighe A.S., Irvine J.N. Combined angiogenic and osteogenic factor delivery for bone regenerative engineering. Curr Pharm Des 2013, 19:3374-3383.
36. Behr B., Sorkin M., Lehnhardt M., Renda A., Longaker M.T., Quarto N. A comparative analysis of the osteogenic effects of BMP-2, FGF-2, and VEGFA in a calvarial defect model. Tissue Eng Part A 2012, 18:1079-1086.
37. Morgan E.F., Mason Z.D., Bishop G., Davis A.D., Wigner N.A., Gerstenfeld L.C., et al. Combined effects of recombinant human BMP-7 (rhBMP-7) and parathyroid hormone (1-34) in metaphyseal bone healing. Bone 2008, 43:1031-1038.
38. Carragee E.J., Hurwitz E.L., Weiner B.K. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011, 11:471-491.
39. Ferretti C., Ripamonti U., Tsiridis E., Kerawala C.J., Mantalaris A., Heliotis M. Osteoinduction: translating preclinical promise into clinical reality. Br J Oral Maxillofac Surg 2010, 48:536-539.
40. Fu R., Selph S., McDonagh M., Peterson K., Tiwari A., Chou R., et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med 2013, 158:890-902.
41. Simmonds M.C., Brown J.V., Heirs M.K., Higgins J.P., Mannion R.J., Rodgers M.A., et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med 2013, 158:877-889.
42. Friedenstein A.J., Petrakova K.V., Kurolesova A.I., Frolova G.P. Heterotopic of bone marrow Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968, 6:230-247.
43. Galderisi U., Giordano A. The Gap Between the Physiological and Therapeutic Roles of Mesenchymal Stem Cells. Med Res Rev 2014, 10.1002/med.21322.
44. Dominici M., Le B.K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
45. Bianco P., Robey P.G., Saggio I., Riminucci M. "Mesenchymal" stem cells in human bone marrow (skeletal stem cells): a critical discussion of their nature, identity, and significance in incurable skeletal disease. Hum Gene Ther 2010, 21:1057-1066.
46. Fernandez Vallone V.B., Romaniuk M.A., Choi H., Labovsky V., Otaegui J., Chasseing N.A. Mesenchymal stem cells and their use in therapy: what has been achieved?. Differentiation 2013, 85:1-10.
47. De B.C., Dell'Accio F., Vanlauwe J., Eyckmans J., Khan I.M., Archer C.W., et al. Mesenchymal multipotency of adult human periosteal cells demonstrated by single-cell lineage analysis. Arthritis Rheum 2006, 54:1209-1221.
48. Evans C.H., Liu F.J., Glatt V., Hoyland J.A., Kirker-Head C., Walsh A., et al. Use of genetically modified muscle and fat grafts to repair defects in bone and cartilage. Eur Cell Mater 2009, 18:96-111.
49. Grcevic D., Pejda S., Matthews B.G., Repic D., Wang L., Li H., et al. In vivo fate mapping identifies mesenchymal progenitor cells. Stem Cells 2012, 30:187-196.
50. Matthews B.G., Grcevic D., Wang L., Hagiwara Y., Roguljic H., Joshi P., et al. Analysis of alphaSMA-Labeled Progenitor Cell Commitment Identifies Notch Signaling as an Important Pathway in Fracture Healing. J Bone Miner Res 2014, 29:1283-1294.
51. Menicanin D., Mrozik K.M., Wada N., Marino V., Shi S., Bartold P.M., et al. Periodontal-Ligament-Derived Stem Cells Exhibit the Capacity for Long-Term Survival, Self-Renewal, and Regeneration of Multiple Tissue Types in Vivo. Stem Cells Dev 2014, 23:1001-1011.
52. Niemeyer P., Fechner K., Milz S., Richter W., Suedkamp N.P., Mehlhorn A.T., et al. Comparison of mesenchymal stem cells from bone marrow and adipose tissue for bone regeneration in a critical size defect of the sheep tibia and the influence of platelet-rich plasma. Biomaterials 2010, 31:3572-3579.
53. Roguljic H., Matthews B.G., Yang W., Cvija H., Mina M., Kalajzic I. In vivo identification of periodontal progenitor cells. J Dent Res 2013, 92:709-715.
54. Arthur A., Zannettino A., Gronthos S. The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. J Cell Physiol 2009, 218:237-245.
55. Gomez-Barrena E., Rosset P., Muller I., Giordano R., Bunu C., Layrolle P., et al. Bone regeneration: stem cell therapies and clinical studies in orthopaedics and traumatology. J Cell Mol Med 2011, 15:1266-1286.
56. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
57. Harichandan A., Buhring H.J. Prospective isolation of human MSC. Best Pract Res Clin Haematol 2011, 24:25-36.
58. Sacchetti B., Funari A., Michienzi S., Di C.S., Piersanti S., Saggio I., et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007, 131:324-336.
59. Caplan A.I. New era of cell-based orthopedic therapies. Tissue Eng Part B Rev 2009, 15:195-200.
60. Lee K., Chan C.K., Patil N., Goodman S.B. Cell therapy for bone regeneration-bench to bedside. J Biomed Mater Res B Appl Biomater 2009, 89:252-263.
61. McCarty R.C., Gronthos S., Zannettino A.C., Foster B.K., Xian C.J. Characterisation and developmental potential of ovine bone marrow derived mesenchymal stem cells. J Cell Physiol 2009, 219:324-333.
62. Stock U.A., Vacanti J.P. Tissue engineering: current state and prospects. Annu Rev Med 2001, 52:443-451.
63. Harvey E.J., Henderson J.E., Vengallatore S.T. Nanotechnology and bone healing. J Orthop Trauma 2010, 24(Suppl. 1):S25-S30.
64. Notices from European Union Institutions Bodies Offices, Agencies Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMA/410/01 rev.3). Off J Eur Union 2011, [2011/C 73/01].
65. Pilia M., Guda T., Appleford M. Development of composite scaffolds for load-bearing segmental bone defects. Biomed Res Int 2013, 2013:458253.
66. Ripamonti U. The induction of bone in osteogenic composites of bone matrix and porous hydroxyapatite replicas: an experimental study on the baboon (Papio ursinus). J Oral Maxillofac Surg 1991, 49:817-830.
67. Ripamonti U. Osteoinduction in porous hydroxyapatite implanted in heterotopic sites of different animal models. Biomaterials 1996, 17:31-35.
68. Habibovic P., van der Valk C.M., van Blitterswijk C.A., De Groot K., Meijer G. Influence of octacalcium phosphate coating on osteoinductive properties of biomaterials. J Mater Sci Mater Med 2004, 15:373-380.
69. Habibovic P., Gbureck U., Doillon C.J., Bassett D.C., van Blitterswijk C.A., Barralet J.E. Osteoconduction and osteoinduction of low-temperature 3D printed bioceramic implants. Biomaterials 2008, 29:944-953.
70. Gosain A.K., Song L., Riordan P., Amarante M.T., Nagy P.G., Wilson C.R., et al. A 1-year study of osteoinduction in hydroxyapatite-derived biomaterials in an adult sheep model: part I. Plast Reconstr Surg 2002, 109:619-630.
71. Gosain A.K., Riordan P.A., Song L., Amarante M.T., Kalantarian B., Nagy P.G., et al. A 1-year study of osteoinduction in hydroxyapatite-derived biomaterials in an adult sheep model: part II. Bioengineering implants to optimize bone replacement in reconstruction of cranial defects. Plast Reconstr Surg 2004, 114:1155-1163.
72. Barrere F., van der Valk C.M., Dalmeijer R.A., Meijer G., van Blitterswijk C.A., De Groot K., et al. Osteogenecity of octacalcium phosphate coatings applied on porous metal implants. J Biomed Mater Res A 2003, 66:779-788.
73. Cao H., Kuboyama N. A biodegradable porous composite scaffold of PGA/beta-TCP for bone tissue engineering. Bone 2010, 46:386-395.
74. Chu T.M., Warden S.J., Turner C.H., Stewart R.L. Segmental bone regeneration using a load-bearing biodegradable carrier of bone morphogenetic protein-2. Biomaterials 2007, 28:459-467.
75. Jegoux F., Goyenvalle E., Cognet R., Malard O., Moreau F., Daculsi G., et al. Reconstruction of irradiated bone segmental defects with a biomaterial associating MBCP+(R), microstructured collagen membrane and total bone marrow grafting: an experimental study in rabbits. J Biomed Mater Res A 2009, 91:1160-1169.
76. Lickorish D., Guan L., Davies J.E. A three-phase, fully resorbable, polyester/calcium phosphate scaffold for bone tissue engineering: Evolution of scaffold design. Biomaterials 2007, 28:1495-1502.
77. Ignatius A.A., Betz O., Augat P., Claes L.E. In vivo investigations on composites made of resorbable ceramics and poly(lactide) used as bone graft substitutes. J Biomed Mater Res 2001, 58:701-709.
78. Xu C., Su P., Chen X., Meng Y., Yu W., Xiang A.P., et al. Biocompatibility and osteogenesis of biomimetic Bioglass-Collagen-Phosphatidylserine composite scaffolds for bone tissue engineering. Biomaterials 2011, 32:1051-1058.
79. Amini A.R., Laurencin C.T., Nukavarapu S.P. Bone tissue engineering: recent advances and challenges. Crit Rev Biomed Eng 2012, 40:363-408.
80. Lee K.Y., Mooney D.J. Hydrogels for tissue engineering. Chem Rev 2001, 101:1869-1879.
81. Slaughter B.V., Khurshid S.S., Fisher O.Z., Khademhosseini A., Peppas N.A. Hydrogels in regenerative medicine. Adv Mater 2009, 21:3307-3329.
82. Park J.B. The use of hydrogels in bone-tissue engineering. Med Oral Patol Oral Cir Bucal 2011, 16:e115-e118.
83. Amini A.R., Adams D.J., Laurencin C.T., Nukavarapu S.P. Optimally porous and biomechanically compatible scaffolds for large-area bone regeneration. Tissue Eng Part A 2012, 18:1376-1388.
84. Hench L.L., Polak J.M. Third-generation biomedical materials. Science 2002, 295:1014-1017.
85. Anderson J.M. Biological responses to materials. Annu Rev Mater Res 2001, 31:81-110.
86. Hollister S.J., Murphy W.L. Scaffold translation: barriers between concept and clinic. Tissue Eng Part B Rev 2011, 17:459-474.
87. Polo-Corrales L., Latorre-Esteves M., Ramirez-Vick J.E. Scaffold design for bone regeneration. J Nanosci Nanotechnol 2014, 14:15-56.
88. Institute for laboratory Animal Research Guide for the care and use of laboratory animals 1996, National Academic Press, Washington, DC.
89. Howard B., Nevalainen T., Perretta G. The COST Manual of Laboratory Animal Care and Use - Refinement, Reduction, and Research 2010, CRC Press.
90. Animal research: a balancing act. Nat Med 2013, 19:1191.
91. Russell W.M.S., Burch R.L. The principles of humane experimental technique 1954, Methuen & Co. Ltd, London.
92. Thompson D.D., Simmons H.A., Pirie C.M., Ke H.Z. FDA Guidelines and animal models for osteoporosis. Bone 1995, 17:125S-133S.
93. Jee W.S., Yao W. Overview: animal models of osteopenia and osteoporosis. J Musculoskelet Neuronal Interact 2001, 1:193-207.
94. Wronski T.J., Cintron M., Dann L.M. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif Tissue Int 1988, 43:179-183.
95. Cesnjaj M., Stavljenic A., Vukicevic S. In vivo models in the study of osteopenias. Eur J Clin Chem Clin Biochem 1991, 29:211-219.
96. Bonucci E., Ballanti P. Osteoporosis--Bone Remodeling and Animal Models. Toxicol Pathol 2013, 10.1177/0192623313512428.
97. Rinotas V., Niti A., Dacquin R., Bonnet N., Stolina M., Han C.Y., et al. Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice. J Bone Miner Res 2014, 29:1158-1169.
98. Melville K.M., Kelly N.H., Khan S.A., Schimenti J.C., Ross F.P., Main R.P., et al. Female mice lacking estrogen receptor-alpha in osteoblasts have compromised bone mass and strength. J Bone Miner Res 2014, 29:370-379.
99. Cortet B. Bone repair in osteoporotic bone: postmenopausal and cortisone-induced osteoporosis. Osteoporos Int 2011, 22:2007-2010.
100. Govindarajan P., Khassawna T., Kampschulte M., Bocker W., Huerter B., Durselen L., et al. Implications of combined ovariectomy and glucocorticoid (dexamethasone) treatment on mineral, microarchitectural, biomechanical and matrix properties of rat bone. Int J Exp Pathol 2013, 94:387-398.
101. Zhang K.J., Zhang J., Kang Z.K., Xue X.M., Kang J.F., Li Y.W., et al. Ibandronate for prevention and treatment of glucocorticoid-induced osteoporosis in rabbits. Rheumatol Int 2012, 32:3405-3411.
102. Baofeng L., Zhi Y., Bei C., Guolin M., Qingshui Y., Jian L. Characterization of a rabbit osteoporosis model induced by ovariectomy and glucocorticoid. Acta Orthop 2010, 81:396-401.
103. Ding M., Cheng L., Bollen P., Schwarz P., Overgaard S. Glucocorticoid induced osteopenia in cancellous bone of sheep: validation of large animal model for spine fusion and biomaterial research. Spine (Phila Pa 1976) 2010, 35:363-370.
104. Rosol T.J., Tannehill-Gregg S.H., LeRoy B.E., Mandl S., Contag C.H. Animal models of bone metastasis. Cancer 2003, 97:748-757.
105. Li X.J., Jee W.S., Chow S.Y., Woodbury D.M. Adaptation of cancellous bone to aging and immobilization in the rat: a single photon absorptiometry and histomorphometry study. Anat Rec 1990, 227:12-24.
106. Tian X., Jee W.S., Li X., Paszty C., Ke H.Z. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 2011, 48:197-201.
107. Gomes P.S., Fernandes M.H. Rodent models in bone-related research: the relevance of calvarial defects in the assessment of bone regeneration strategies. Lab Anim 2011, 45:14-24.
108. Mills L.A., Simpson A.H. In vivo models of bone repair. J Bone Joint Surg Br 2012, 94:865-874.
109. Horner E.A., Kirkham J., Wood D., Curran S., Smith M., Thomson B., et al. Long bone defect models for tissue engineering applications: criteria for choice. Tissue Eng Part B Rev 2010, 16:263-271.
110. Reifenrath J., Angrisani N., Lalk M., Besdo S. Replacement, refinement, and reduction: Necessity of standardization and computational models for long bone fracture repair in animals. J Biomed Mater Res A 2014, 102:2884-2900.
111. Einhorn T.A., Lane J.M., Burstein A.H., Kopman C.R., Vigorita V.J. The healing of segmental bone defects induced by demineralized bone matrix. A radiographic and biomechanical study. J Bone Joint Surg Am 1984, 66:274-279.
112. Betz O.B., Betz V.M., Nazarian A., Pilapil C.G., Vrahas M.S., Bouxsein M.L., et al. Direct percutaneous gene delivery to enhance healing of segmental bone defects. J Bone Joint Surg Am 2006, 88:355-365.
113. Bagi C.M., Hanson N., Andresen C., Pero R., Lariviere R., Turner C.H., et al. The use of micro-CT to evaluate cortical bone geometry and strength in nude rats: correlation with mechanical testing, pQCT and DXA. Bone 2006, 38:136-144.
114. Tortelli F., Tasso R., Loiacono F., Cancedda R. The development of tissue-engineered bone of different origin through endochondral and intramembranous ossification following the implantation of mesenchymal stem cells and osteoblasts in a murine model. Biomaterials 2010, 31:242-249.
115. Eyckmans J., Luyten F.P. Species specificity of ectopic bone formation using periosteum-derived mesenchymal progenitor cells. Tissue Eng 2006, 12:2203-2213.
116. Jee W.S., Ma Y. Animal models of immobilization osteopenia. Morphologie 1999, 83:25-34.
117. Auer J.A., Goodship A., Arnoczky S., Pearce S., Price J., Claes L., et al. Refining animal models in fracture research: seeking consensus in optimising both animal welfare and scientific validity for appropriate biomedical use. BMC Musculoskelet Disord 2007, 8:72.
118. Pearce A.I., Richards R.G., Milz S., Schneider E., Pearce S.G. Animal models for implant biomaterial research in bone: a review. Eur Cell Mater 2007, 13:1-10.
119. Vannabouathong C., Sprague S., Bhandari M. Guidelines for fracture healing assessments in clinical trials Part I: definitions and endpoint committees. Injury 2011, 42:314-316.
120. Reddi A.H., Huggins C. Biochemical sequences in the transformation of normal fibroblasts in adolescent rats. Proc Natl Acad Sci U S A 1972, 69:1601-1605.
121. Van Eijden T.M. Biomechanics of the mandible. Crit Rev Oral Biol Med 2000, 11:123-136.
122. Bidez M.W., Misch C.E. Issues in bone mechanics related to oral implants. Implant Dent 1992, 1:289-294.
123. Bergman R.J., Gazit D., Kahn A.J., Gruber H., McDougall S., Hahn T.J. Age-related changes in osteogenic stem cells in mice. J Bone Miner Res 1996, 11:568-577.
124. Bowman B.M., Miller S.C. Skeletal mass, chemistry, and growth during and after multiple reproductive cycles in the rat. Bone 1999, 25:553-559.
125. Bowman B.M., Siska C.C., Miller S.C. Greatly increased cancellous bone formation with rapid improvements in bone structure in the rat maternal skeleton after lactation. J Bone Miner Res 2002, 17:1954-1960.
126. Naylor K.E., Iqbal P., Fledelius C., Fraser R.B., Eastell R. The effect of pregnancy on bone density and bone turnover. J Bone Miner Res 2000, 15:129-137.
127. Vajda E.G., Bowman B.M., Miller S.C. Cancellous and cortical bone mechanical properties and tissue dynamics during pregnancy, lactation, and postlactation in the rat. Biol Reprod 2001, 65:689-695.
128. Lelovas P.P., Xanthos T.T., Thoma S.E., Lyritis G.P., Dontas I.A. The laboratory rat as an animal model for osteoporosis research. Comp Med 2008, 58:424-430.
129. Dumic-Cule I., Draca N., Luetic A.T., Jezek D., Rogic D., Grgurevic L., et al. TSH Prevents Bone Resorption and with Calcitriol Synergistically Stimulates Bone Formation in Rats with Low Levels of Calciotropic Hormones. Horm Metab Res 2014, 46:305-312.
130. Martini L., Fini M., Giavaresi G., Giardino R. Sheep model in orthopedic research: a literature review. Comp Med 2001, 51:292-299.
131. O'Loughlin P.F., Morr S., Bogunovic L., Kim A.D., Park B., Lane J.M. Selection and development of preclinical models in fracture-healing research. J Bone Joint Surg Am 2008, 90(Suppl. 1):79-84.
132. Bagi C.M., Berryman E., Moalli M.R. Comparative bone anatomy of commonly used laboratory animals: implications for drug discovery. Comp Med 2011, 61:76-85.
133. Schimandle J.H., Boden S.D. Spine update. The use of animal models to study spinal fusion. Spine (Phila Pa 1976) 1994, 19. [1998-2006].
134. Kilborn S.H., Trudel G., Uhthoff H. Review of growth plate closure compared with age at sexual maturity and lifespan in laboratory animals. Contemp Top Lab Anim Sci 2002, 41:21-26.
135. Swindle M.M., Smith A.C. Comparative anatomy and physiology of the pig. Lab Anim Sci 1998, 25:11-21.
136. Tsutsumi H., Katagiri K., Takeda S., Nasu T., Igarashi S., Tanigawa M., et al. Standardized data and relationship between bone growth and bone metabolism in female Gottingen minipigs. Exp Anim 2004, 53:331-337.
137. Cheverud J.M. Epiphyseal union and dental eruption Macaca mulatta. Am J Phys Anthropol 1981, 56:157-167.
138. ENLOW D.H. Functions of the Haversian system. Am J Anat 1962, 110:269-305.
139. Frost H.M., Jee W.S. On the rat model of human osteopenias and osteoporoses. Bone Miner 1992, 18:227-236.
140. Kalu D.N. The ovariectomized rat model of postmenopausal bone loss. Bone Miner 1991, 15:175-191.
141. Miller S.C., Bowman B.M., Jee W.S. Available animal models of osteopenia-small and large. Bone 1995, 17:117S-123S.
142. Frost H.M. Human Haversian system measurements. Henry Ford Hosp Med Bull 1961, 9:145-147.
143. Erben R.G. Trabecular and endocortical bone surfaces in the rat: modeling or remodeling?. Anat Rec 1996, 246:39-46.
144. Vignery A., Baron R. Dynamic histomorphometry of alveolar bone remodeling in the adult rat. Anat Rec 1980, 196:191-200.
145. Tibbitts J., Cavagnaro J.A., Haller C.A., Marafino B., Andrews P.A., Sullivan J.T. Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals. Regul Toxicol Pharmacol 2010, 58:243-251.
146. ICH harmonized tripartite guideline, Preclinical safety evaluation of biotechnology-derived pharmaceuticals. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011.
147. Neyt J.G., Buckwalter J.A., Carroll N.C. Use of animal models in musculoskeletal research. Iowa Orthop J 1998, 18:118-123.
148. Wang X., Mabrey J.D., Agrawal C.M. An interspecies comparison of bone fracture properties. Biomed Mater Eng 1998, 8:1-9.
149. Han N., Zhang P.X., Wang W.B., Han D.C., Chen J.H., Zhan H.B., et al. A new experimental model to study healing process of metaphyseal fracture. Chin Med J (Engl) 2012, 125:676-679.
150. Kim I.S., Cho T.H., Lee Z.H., Hwang S.J. Bone regeneration by transplantation of human mesenchymal stromal cells in a rabbit mandibular distraction osteogenesis model. Tissue Eng Part A 2013, 19:66-78.
151. Tang Z.L., Zhang W.J., Wang D.X., Chen J.M., Ma H., Wu D.R. An Experimental Study Addressing the Promotion of Mandibular Defect Repair Through the Intermittent Subcutaneous Injection of Parathyroid Hormone. J Oral Maxillofac Surg 2014, 72:419-430.
152. Lim H.P., Mercado-Pagan A.E., Yun K.D., Kang S.S., Choi T.H., Bishop J., et al. The effect of rhBMP-2 and PRP delivery by biodegradable beta-tricalcium phosphate scaffolds on new bone formation in a non-through rabbit cranial defect model. J Mater Sci Mater Med 2013, 24:1895-1903.
153. Hassanein A.H., Couto R.A., Nedder A., Zielins E.R., Greene A.K. Critical-size defect ossification: effect of leporid age in a cranioplasty model. J Craniofac Surg 2011, 22:2341-2343.
154. Rolfing J.H., Bunger C. Recommendations regarding the rabbit posterolateral spinal fusion model. J Orthop Res 2013, 31:1860.
155. Riordan A.M., Rangarajan R., Balts J.W., Hsu W.K., Anderson P.A. Reliability of the rabbit postero-lateral spinal fusion model: A meta-analysis. J Orthop Res 2013, 31:1261-1269.
156. Sato T., Shimizu H., Beppu M., Takagi M. Effects on bone union and prevention of tendon adhesion by new porous anti-adhesive poly L-lactide-co-epsilon-caprolactone membrane in a rabbit model. Hand Surg 2013, 18:1-10.
157. Oshima S., Ishikawa M., Mochizuki Y., Kobayashi T., Yasunaga Y., Ochi M. Enhancement of bone formation in an experimental bony defect using ferumoxide-labelled mesenchymal stromal cells and a magnetic targeting system. J Bone Joint Surg Br 2010, 92:1606-1613.
158. Kuhn J.L., Goldstein S.A., Ciarelli M.J., Matthews L.S. The limitations of canine trabecular bone as a model for human: a biomechanical study. J Biomech 1989, 22:95-107.
159. Hasiwa N., Bailey J., Clausing P., Daneshian M., Eileraas M., Farkas S., et al. Critical evaluation of the use of dogs in biomedical research and testing in Europe. ALTEX 2011, 28:326-340.
160. Litten-Brown J.C., Corson A.M., Clarke L. Porcine models for the metabolic syndrome, digestive and bone disorders: a general overview. Animal 2010, 4:899-920.
161. Mosekilde L., Kragstrup J., Richards A. Compressive strength, ash weight, and volume of vertebral trabecular bone in experimental fluorosis in pigs. Calcif Tissue Int 1987, 40:318-322.
162. Raab D.M., Crenshaw T.D., Kimmel D.B., Smith E.L. A histomorphometric study of cortical bone activity during increased weight-bearing exercise. J Bone Miner Res 1991, 6:741-749.
163. Teo J.C., Si-Hoe K.M., Keh J.E., Teoh S.H. Relationship between CT intensity, micro-architecture and mechanical properties of porcine vertebral cancellous bone. Clin Biomech (Bristol, Avon) 2006, 21:235-244.
164. Walsh M.P., Wijdicks C.A., Parker J.B., Hapa O., LaPrade R.F. A comparison between a retrograde interference screw, suture button, and combined fixation on the tibial side in an all-inside anterior cruciate ligament reconstruction: a biomechanical study in a porcine model. Am J Sports Med 2009, 37:160-167.
165. Forster R., Bode G., Ellegaard L., van der Laan J.W. The RETHINK project-minipigs as models for the toxicity testing of new medicines and chemicals: an impact assessment. J Pharmacol Toxicol Methods 2010, 62:158-159.
166. van Mierlo G.J., Cnubben N.H., Kuper C.F., Wolthoorn J., van Meeteren-Kreikamp A.P., Nagtegaal M.M., et al. The Gottingen minipig(R) as an alternative non-rodent species for immunogenicity testing: a demonstrator study using the IL-1 receptor antagonist anakinra. J Immunotoxicol 2013, 10:96-105.
167. van Mierlo G.J., Cnubben N.H., Wouters D., Wolbink G.J., Hart M.H., Rispens T., et al. The minipig as an alternative non-rodent model for immunogenicity testing using the TNFalpha blockers adalimumab and infliximab. J Immunotoxicol 2014, 11:62-71.
168. Anzenbacherova E., Anzenbacher P., Svoboda Z., Ulrichova J., Kvetina J., Zoulova J., et al. Minipig as a model for drug metabolism in man: comparison of in vitro and in vivo metabolism of propafenone. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003, 147:155-159.
169. Boyce R.W., Ebert D.C., Youngs T.A., Paddock C.L., Mosekilde L., Stevens M.L., et al. Unbiased estimation of vertebral trabecular connectivity in calcium-restricted ovariectomized minipigs. Bone 1995, 16:637-642.
170. Kim S.W., Kim K.S., Solis C.D., Lee M.S., Hyun B.H. Development of osteoporosis animal model using micropigs. Lab Anim Res 2013, 29:174-177.
171. Mosekilde L., Weisbrode S.E., Safron J.A., Stills H.F., Jankowsky M.L., Ebert D.C., et al. Calcium-restricted ovariectomized Sinclair S-1 minipigs: an animal model of osteopenia and trabecular plate perforation. Bone 1993, 14:379-382.
172. Mosekilde L., Weisbrode S.E., Safron J.A., Stills H.F., Jankowsky M.L., Ebert D.C., et al. Evaluation of the skeletal effects of combined mild dietary calcium restriction and ovariectomy in Sinclair S-1 minipigs: a pilot study. J Bone Miner Res 1993, 8:1311-1321.
173. Newman E., Turner A.S., Wark J.D. The potential of sheep for the study of osteopenia: current status and comparison with other animal models. Bone 1995, 16:277S-284S.
174. Reichert J.C., Cipitria A., Epari D.R., Saifzadeh S., Krishnakanth P., Berner A., et al. A tissue engineering solution for segmental defect regeneration in load-bearing long bones. Sci Transl Med 2012, 4:141ra93.
175. Kon E., Muraglia A., Corsi A., Bianco P., Marcacci M., Martin I., et al. Autologous bone marrow stromal cells loaded onto porous hydroxyapatite ceramic accelerate bone repair in critical-size defects of sheep long bones. J Biomed Mater Res 2000, 49:328-337.
176. Klaue K., Knothe U., Anton C., Pfluger D.H., Stoddart M., Masquelet A.C., et al. Bone regeneration in long-bone defects: tissue compartmentalisation? In vivo study on bone defects in sheep. Injury 2009, 40(Suppl. 4):S95-S102.
177. Cancedda R., Giannoni P., Mastrogiacomo M. A tissue engineering approach to bone repair in large animal models and in clinical practice. Biomaterials 2007, 28:4240-4250.
178. Viateau V., Guillemin G., Bousson V., Oudina K., Hannouche D., Sedel L., et al. Long-bone critical-size defects treated with tissue-engineered grafts: a study on sheep. J Orthop Res 2007, 25:741-749.
179. Reichert J.C., Wullschleger M.E., Cipitria A., Lienau J., Cheng T.K., Schutz M.A., et al. Custom-made composite scaffolds for segmental defect repair in long bones. Int Orthop 2011, 35:1229-1236.
180. Reichert J.C., Woodruff M.A., Friis T., Quent V.M., Gronthos S., Duda G.N., et al. Ovine bone- and marrow-derived progenitor cells and their potential for scaffold-based bone tissue engineering applications in vitro and in vivo. J Tissue Eng Regen Med 2010, 4:565-576.
181. Reichert J.C., Epari D.R., Wullschleger M.E., Saifzadeh S., Steck R., Lienau J., et al. Establishment of a preclinical ovine model for tibial segmental bone defect repair by applying bone tissue engineering strategies. Tissue Eng Part B Rev 2010, 16:93-104.
182. Berner A., Reichert J.C., Woodruff M.A., Saifzadeh S., Morris A.J., Epari D.R., et al. Autologous vs. allogenic mesenchymal progenitor cells for the reconstruction of critical sized segmental tibial bone defects in aged sheep. Acta Biomater 2013, 9:7874-7884.
183. Mastrogiacomo M., Papadimitropoulos A., Cedola A., Peyrin F., Giannoni P., Pearce S.G., et al. Engineering of bone using bone marrow stromal cells and a silicon-stabilized tricalcium phosphate bioceramic: evidence for a coupling between bone formation and scaffold resorption. Biomaterials 2007, 28:1376-1384.
184. Giannoni P., Mastrogiacomo M., Alini M., Pearce S.G., Corsi A., Santolini F., et al. Regeneration of large bone defects in sheep using bone marrow stromal cells. J Tissue Eng Regen Med 2008, 2:253-262.
185. Jerome C.P., Turner C.H., Lees C.J. Decreased bone mass and strength in ovariectomized cynomolgus monkeys (Macaca fascicularis). Calcif Tissue Int 1997, 60:265-270.
186. Jerome C.P. Primate models of osteoporosis. Lab Anim Sci 1998, 48:618-622.
187. Jerome C.P., Peterson P.E. Nonhuman primate models in skeletal research. Bone 2001, 29:1-6.
188. Sauer U., Phillips B., Reid K., Schmit V., Jennings M. Ethical review of projects involving non-human primates funded under the European Union's 7th Research Framework Programme. Altern Lab Anim 2013, 41:271-306.
189. Bagi C.M., Volberg M., Moalli M., Shen V., Olson E., Hanson N., et al. Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture. Anat Rec (Hoboken) 2007, 290:1005-1016.
190. Abbott D.H., Barnett D.K., Colman R.J., Yamamoto M.E., Schultz-Darken N.J. Aspects of common marmoset basic biology and life history important for biomedical research. Comp Med 2003, 53:339-350.
191. Food and Drug Administration Guidelines for Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis 1994, FDA Division of Metabolism and Endocrine Drug Products, Washington, DC.
192. European and Medicines Agency Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis, CPMP/EWP/552/95. Rev 2007, 2.
193. Food and Drug Administration Guidance for Industry, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Division of Drug Information 2005, Center for Drug Evaluation and Research, Rockville, MD, USA.
194. Long T., Zhu Z., Awad H.A., Schwarz E.M., Hilton M.J., Dong Y. The effect of mesenchymal stem cell sheets on structural allograft healing of critical sized femoral defects in mice. Biomaterials 2014, 35:2752-2759.
195. Breitbart E.A., Meade S., Azad V., Yeh S., Al-Zube L., Lee Y.S., et al. Mesenchymal stem cells accelerate bone allograft incorporation in the presence of diabetes mellitus. J Orthop Res 2010, 28:942-949.
196. Srouji S., Livne E. Bone marrow stem cells and biological scaffold for bone repair in aging and disease. Mech Ageing Dev 2005, 126:281-287.
197. Zou X.H., Cai H.X., Yin Z., Chen X., Jiang Y.Z., Hu H., et al. A novel strategy incorporated the power of mesenchymal stem cells to allografts for segmental bone tissue engineering. Cell Transplant 2009, 18:433-441.
198. Pang L., Hao W., Jiang M., Huang J., Yan Y., Hu Y. Bony defect repair in rabbit using hybrid rapid prototyping polylactic-co-glycolic acid/beta-tricalciumphosphate collagen I/apatite scaffold and bone marrow mesenchymal stem cells. Indian J Orthop 2013, 47:388-394.
199. Rathbone C.R., Guda T., Singleton B.M., Oh D.S., Appleford M.R., Ong J.L., et al. Effect of cell-seeded hydroxyapatite scaffolds on rabbit radius bone regeneration. J Biomed Mater Res A 2014, 102:1458-1466.
200. Kang S.H., Chung Y.G., Oh I.H., Kim Y.S., Min K.O., Chung J.Y. Bone regeneration potential of allogeneic or autogeneic mesenchymal stem cells loaded onto cancellous bone granules in a rabbit radial defect model. Cell Tissue Res 2014, 355:81-88.
201. Bruder S.P., Kraus K.H., Goldberg V.M., Kadiyala S. The effect of implants loaded with autologous mesenchymal stem cells on the healing of canine segmental bone defects. J Bone Joint Surg Am 1998, 80:985-996.
202. Arinzeh T.L., Peter S.J., Archambault M.P., van den Bos C., Gordon S., Kraus K., et al. Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am 2003, 85-A:1927-1935.
203. Wang C., Wang Z., Li A., Bai F., Lu J., Xu S., et al. Repair of segmental bone-defect of goat's tibia using a dynamic perfusion culture tissue engineering bone. J Biomed Mater Res A 2010, 92:1145-1153.
204. Field J.R., McGee M., Stanley R., Ruthenbeck G., Papadimitrakis T., Zannettino A., et al. The efficacy of allogeneic mesenchymal precursor cells for the repair of an ovine tibial segmental defect. Vet Comp Orthop Traumatol 2011, 24:113-121.
205. Liu G., Zhao L., Zhang W., Cui L., Liu W., Cao Y. Repair of goat tibial defects with bone marrow stromal cells and beta-tricalcium phosphate. J Mater Sci Mater Med 2008, 19:2367-2376.
206. Bahney C.S., Hu D.P., Taylor A.J., Ferro F., Britz H.M., Hallgrimsson B., et al. Stem Cell Derived Endochondral Cartilage Stimulates Bone Healing by Tissue Transformation. J Bone Miner Res 2014, 29:1269-1282.
207. Bruder S.P., Kurth A.A., Shea M., Hayes W.C., Jaiswal N., Kadiyala S. Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells. J Orthop Res 1998, 16:155-162.
208. Meinel L., Betz O., Fajardo R., Hofmann S., Nazarian A., Cory E., et al. Silk based biomaterials to heal critical sized femur defects. Bone 2006, 39:922-931.
209. Amorosa L.F., Lee C.H., Aydemir A.B., Nizami S., Hsu A., Patel N.R., et al. Physiologic load-bearing characteristics of autografts, allografts, and polymer-based scaffolds in a critical sized segmental defect of long bone: an experimental study. Int J Nanomedicine 2013, 8:1637-1643.
210. Niemeyer P., Szalay K., Luginbuhl R., Sudkamp N.P., Kasten P. Transplantation of human mesenchymal stem cells in a non-autogenous setting for bone regeneration in a rabbit critical-size defect model. Acta Biomater 2010, 6:900-908.
211. Niemeyer P., Schonberger T.S., Hahn J., Kasten P., Fellenberg J., Suedkamp N., et al. Xenogenic transplantation of human mesenchymal stem cells in a critical size defect of the sheep tibia for bone regeneration. Tissue Eng Part A 2010, 16:33-43.
212. Tsang W.P., Shu Y., Kwok P.L., Zhang F., Lee K.K., Tang M.K., et al. CD146+ human umbilical cord perivascular cells maintain stemness under hypoxia and as a cell source for skeletal regeneration. PLoS One 2013, 8:e76153.
213. Zwingenberger S., Yao Z., Jacobi A., Vater C., Valladares R.D., Li C., et al. Enhancement of BMP-2 Induced Bone Regeneration by SDF-1alpha Mediated Stem Cell Recruitment. Tissue Eng Part A 2014, 20:810-818.
214. Atesok K., Li R., Stewart D.J., Schemitsch E.H. Endothelial progenitor cells promote fracture healing in a segmental bone defect model. J Orthop Res 2010, 28:1007-1014.
215. James A.W., Zara J.N., Corselli M., Chiang M., Yuan W., Nguyen V., et al. Use of human perivascular stem cells for bone regeneration. J Vis Exp 2012, e2952.
216. Fan Z.X., Lu Y., Deng L., Li X.Q., Zhi W., Li-Ling J., et al. Placenta- versus bone-marrow-derived mesenchymal cells for the repair of segmental bone defects in a rabbit model. FEBS J 2012, 279:2455-2465.
217. Kim A., Kim D.H., Song H.R., Kang W.H., Kim H.J., Lim H.C., et al. Repair of rabbit ulna segmental bone defect using freshly isolated adipose-derived stromal vascular fraction. Cytotherapy 2012, 14:296-305.
218. Gazit D., Turgeman G., Kelley P., Wang E., Jalenak M., Zilberman Y., et al. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy. J Gene Med 1999, 1:121-133.
219. Xie C., Reynolds D., Awad H., Rubery P.T., Pelled G., Gazit D., et al. Structural bone allograft combined with genetically engineered mesenchymal stem cells as a novel platform for bone tissue engineering. Tissue Eng 2007, 13:435-445.
220. Corn D.J., Kim Y., Krebs M.D., Mounts T., Molter J., Gerson S., et al. Imaging early stage osteogenic differentiation of mesenchymal stem cells. J Orthop Res 2013, 31:871-879.
221. Hoffman M.D., Xie C., Zhang X., Benoit D.S. The effect of mesenchymal stem cells delivered via hydrogel-based tissue engineered periosteum on bone allograft healing. Biomaterials 2013, 34:8887-8898.
222. Huang C., Tang M., Yehling E., Zhang X. Overexpressing sonic hedgehog Peptide restores periosteal bone formation in a murine bone allograft transplantation model. Mol Ther 2014, 22:430-439.
223. Rutherford R.B., Moalli M., Franceschi R.T., Wang D., Gu K., Krebsbach P.H. Bone morphogenetic protein-transduced human fibroblasts convert to osteoblasts and form bone in vivo. Tissue Eng 2002, 8:441-452.
224. Tsuchida H., Hashimoto J., Crawford E., Manske P., Lou J. Engineered allogeneic mesenchymal stem cells repair femoral segmental defect in rats. J Orthop Res 2003, 21:44-53.
225. Guo X., Zheng Q., Kulbatski I., Yuan Q., Yang S., Shao Z., et al. Bone regeneration with active angiogenesis by basic fibroblast growth factor gene transfected mesenchymal stem cells seeded on porous beta-TCP ceramic scaffolds. Biomed Mater 2006, 1:93-99.
226. Cao L., Liu X., Liu S., Jiang Y., Zhang X., Zhang C., et al. Experimental repair of segmental bone defects in rabbits by angiopoietin-1 gene transfected MSCs seeded on porous beta-TCP scaffolds. J Biomed Mater Res B Appl Biomater 2012, 100:1229-1236.
227. Kasten P., Beverungen M., Lorenz H., Wieland J., Fehr M., Geiger F. Comparison of platelet-rich plasma and VEGF-transfected mesenchymal stem cells on vascularization and bone formation in a critical-size bone defect. Cells Tissues Organs 2012, 196:523-533.
228. Chen Q., Yang Z., Sun S., Huang H., Sun X., Wang Z., et al. Adipose-derived stem cells modified genetically in vivo promote reconstruction of bone defects. Cytotherapy 2010, 12:831-840.
229. Ren M.L., Peng W., Yang Z.L., Sun X.J., Zhang S.C., Wang Z.G., et al. Allogeneic adipose-derived stem cells with low immunogenicity constructing tissue-engineered bone for repairing bone defects in pigs. Cell Transplant 2012, 21:2711-2721.
230. Kanczler J.M., Ginty P.J., Barry J.J., Clarke N.M., Howdle S.M., Shakesheff K.M., et al. The effect of mesenchymal populations and vascular endothelial growth factor delivered from biodegradable polymer scaffolds on bone formation. Biomaterials 2008, 29:1892-1900.
231. Kanczler J.M., Ginty P.J., White L., Clarke N.M., Howdle S.M., Shakesheff K.M., et al. The effect of the delivery of vascular endothelial growth factor and bone morphogenic protein-2 to osteoprogenitor cell populations on bone formation. Biomaterials 2010, 31:1242-1250.
232. Kirker-Head C., Karageorgiou V., Hofmann S., Fajardo R., Betz O., Merkle H.P., et al. BMP-silk composite matrices heal critically sized femoral defects. Bone 2007, 41:247-255.
233. Burastero G., Scarfi S., Ferraris C., Fresia C., Sessarego N., Fruscione F., et al. The association of human mesenchymal stem cells with BMP-7 improves bone regeneration of critical-size segmental bone defects in athymic rats. Bone 2010, 47:117-126.
234. Kasten P., Vogel J., Geiger F., Niemeyer P., Luginbuhl R., Szalay K. The effect of platelet-rich plasma on healing in critical-size long-bone defects. Biomaterials 2008, 29:3983-3992.
235. El Backly R.M., Zaky S.H., Muraglia A., Tonachini L., Brun F., Canciani B., et al. A platelet-rich plasma-based membrane as a periosteal substitute with enhanced osteogenic and angiogenic properties: a new concept for bone repair. Tissue Eng Part A 2013, 19:152-165.
236. Brodke D., Pedrozo H.A., Kapur T.A., Attawia M., Kraus K.H., Holy C.E., et al. Bone grafts prepared with selective cell retention technology heal canine segmental defects as effectively as autograft. J Orthop Res 2006, 24:857-866.
237. Di B.C., Aldini N.N., Lucarelli E., Dozza B., Frisoni T., Martini L., et al. Osteogenic protein-1 associated with mesenchymal stem cells promote bone allograft integration. Tissue Eng Part A 2010, 16:2967-2976.
238. Armitage P., Barry G., Matthews J.N.S. Statistical methods in medical research 2002, Blackwell Science.
239. Littel R.C., Milliken G.A., Stroup W.W., Wolfinger R.D., Schabenberger O. SAS for mixed models 2006, SAS Institute Inc., Cary, NC, USA.
240. Song K., Krause C., Shi S., Patterson M., Suto R., Grgurevic L., et al. Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineered BMPs with superior agonist activity. J Biol Chem 2010, 285:12169-12180.
241. Grgurevic L., Macek B., Mercep M., Jelic M., Smoljanovic T., Erjavec I., et al. Bone morphogenetic protein (BMP)1-3 enhances bone repair. Biochem Biophys Res Commun 2011, 408:25-31.